Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $62.00 price target on Regenxbio Inc. (NASDAQ: RGNX) highlighting 5 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE